McGee Kiaran P, Hwang Ken-Pin, Sullivan Daniel C, Kurhanewicz John, Hu Yanle, Wang Jihong, Li Wen, Debbins Josef, Paulson Eric, Olsen Jeffrey R, Hua Chia-Ho, Warner Lizette, Ma Daniel, Moros Eduardo, Tyagi Neelam, Chung Caroline
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Imaging Physics, Division of Diagnostic Imaging, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.
Med Phys. 2021 Jul;48(7):e697-e732. doi: 10.1002/mp.14884. Epub 2021 May 20.
A magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
磁共振（MR）生物标志物是一种可测量的定量特征，它是正常生物学和致病过程的指标，或是源自MR成像过程的对治疗干预的反应。MR生物标志物通过量化正常组织与病理组织功能以及对放疗和化疗的毒性，以更精确地靶向疾病，从而促进癌症个性化治疗，具有巨大潜力。这两者都有可能提高治疗比率，并能更早、更准确地监测治疗反应。MR持续融入常规临床放射治疗（RT）计划以及MR引导放射治疗系统的开发，为MR生物标志物实现个性化和改善临床结果提供了新机遇。然而，其合理应用必须基于对生物标志物信号的物理起源、与潜在生物学过程的关系及其优势和局限性的了解。本报告的目的是提供一种教育资源，描述MR生物标志物、用于量化它们的技术、在放射肿瘤学应用背景下的优缺点，以确保其在该领域的合理使用和应用。
